Declarations of Interest

S6 ESTABLISHING THE TRUE INCIDENCE OF HOSPITALISED COMMUNITY ACQUIRED PNEUMONIA (CAP) IN THE UK: A HOSPITAL EPISODE STATISTICS (HES) ANALYSIS

10.1136/thoraxjnl-2017-210983.457

This research was sponsored by Pfizer.

J Campling, D Jones, G Ellsbury, C Czudek, and H Madhava are employees of Pfizer and have no conflicts of interest to declare.

M Slack has received personal fees from GSK, Pfizer, AstraZeneca and Sanofi Pasteur as a speaker at international meetings and as a member of advisory boards (outside the scope of the submitted work). She has also worked as a contractor for Pfizer. HES analyses were done by Harvey Walsh Health Informatics, and medical writing support was provided by Richard Watt at Sudler, both of which were funded by Pfizer.

S93 EFFECT OF LUMACAFTOR/IVACAFTOR ON TOTAL, BRONCHIECTASIS, AND AIR TRAPPING COMPUTED TOMOGRAPHY (CT) SCORES IN CHILDREN HOMOZYGOUS FOR F508DEL-CFTR: EXPLORATORY IMAGING SUBSTUDY

10.1136/thoraxjnl-2017-210983.458

AS Brody reports personal fees from Vertex Pharmaceuticals during the conduct of the study.

S Nagle reports personal consulting fees from Vertex Pharmaceuticals during the conduct of the study; non-financial support from GE Healthcare (institution/department support).

C Hug, G Marigowda, D Waltz, L Wang are employees of Vertex Pharmaceuticals and may hold stock and/or stock options in the company.

J Goldin reports 'other' conflicts – Founder of MedQIA during the conduct of the study.

F Ratjen reports grants and personal fees from Vertex Pharmaceuticals, personal consulting fees from Novartis, Bayer, Roche, Genetech, and Prosteostasis.

S96 AN OPEN-LABEL EXTENSION (EXT) STUDY OF LUMACAFTOR/IVACAFTOR (LUM/IVA) THERAPY IN PATIENTS AGED 6 TO 11 YEARS WITH CYSTIC FIBROSIS (CF) HOMOZYGOUS FOR F508DEL-CFTR

10.1136/thoraxjnl-2017-210983.459

M Chilvers and P Black have nothing to disclose.

S Tian, G Marigowda, M Bsharat, C Hug are employees of Vertex Pharmaceuticals and may hold stock and/or stock options in the company.

M Solomon reports involvement in clinical trials with Vertex Pharmaceuticals. (sponsored the clinical trial, no money directly to PI)

M Rosenfeld reports that her institution has received funding from Vertex Pharmaceuticals for research on which she is

an investigator. She also has served as a consultant for Vertex Pharmaceuticals.

G Sawicki reports personal fees from Vertex Pharmaceuticals outside the submitted work. (advisory boards)

J Hoppe reports grant funding from the Cystic Fibrosis Foundation outside the submitted work.

P19 IMPACT OF MONTH OF INITIATION OF OMALIZUMAB ON TREATMENT OF SEVERE ALLERGIC ASTHMA, A SUB-ANALYSIS OF THE APEX II STUDY

10.1136/thoraxjnl-2017-210983.460

R Niven has received an unrestricted grant of £10,000 from Novartis in 2010 towards development of clinical services at the University Hospital of South Manchester. He has run preceptorship programmes in 2015 and 2106. These programmes have resulted in payment to the University Hospital of south Manchester for amounts not exceeding £10,000. Dr Niven has also performed lecturing at Pharmaceutically sponsored meetings for the following pharmaceutical companies in the last 3 years:- Astra Zeneca (<£1,000), Boehringer Ingelheim (<£2,000) Boston scientific (<£5,000) Chiesi (<£1,000), Novartis < £10,000, Napp (<£2,000), Teva (<£2,000). Dr Niven has sat on advisory boards for the following companies in the last 3 years, (Astra Zeneca, Boehringer Ingelheim, Boston scientific, Chiesi, GSK, Novartis Vectura and Teva), receiving reimbursement not exceeding £5,000 per company. Dr Niven has received sponsorship support to attend international academic meetings from Astra Zeneca, Boehringer Ingelheim, Novartis, GSK, Chiesi and TEVA. Dr Niven, (or any members of his family) has no shares or any pecuniary interest in any pharmaceutical industry and has no share holdings or dividends and is not a paid consultant for any company.

D Saralaya has no conflicts of interest pertaining to this abstract

R Chaudhuri has been a member of advisory board meetings for Novartis, AstraZeneca, GSK and Teva, been invited to international conferences by Novartis, Boehringer, AstraZeneca and Napp and received educational research grants from Novartis and Aerocrine.

M Masoli attended a Novartis advisory board meeting.

I Clifton has received honoraria from Novartis, and GSK. He has received travel grants to attend educational meetings from Novartis, GSK, Gilead and AstraZeneca.

AH Mansur has received personal and institutional payments for speaking, participation in advisory board meetings and other education activities from several pharmaceutical companies that include AZ, GSK, BI, Novartis, Teva, NAPP, Chiesi

S Hollywood Employee at Novartis. This study was funded by Novartis, who participated in the study design, interpretation of data, and review and approval of the abstract.

S Mclain-Smith employee of pH Associates; carried out data analysis and provided medical writing support.

A Menzies-Gow has attended advisory boards for GlaxoSmithKline, Novartis, AstraZeneca, Boehringer Ingelheim, and Teva. He has received speaker fees from Novartis, AstraZeneca, Vectura, Boehringer Ingelheim, and Teva. He has received clinical trial funding from AstraZeneca and has participated in research with Hoffmann La Roche, GlaxoSmithKline, and Boehringer Ingelheim, for which his institution has